FILANA THERAPEUTICS, INC.
FLNANasdaq
$1.06
↓ -1.9%Jul 17 close · end-of-day
Price
1Y↓ -48.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$77.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-114.3%
ROIC
—
Debt / Equity
—
Net Cash
$86.6M
Return 1Y
-49.5%
Company profile
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial.
- CEO
- Remi Barbier
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Texas
- Website
- cassavasciences.com
Management & directors
- Barry RichardPresident & CEO
- Cook Robert ChristopherChief Operating & Legal Office
Roles derived from SEC Form 4 filings.
Earnings
FLNA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.4M | -$32.9M | -$80.0M | -$106.0M | -$141.4M | -$95.4M |
| Net income | -$6.3M | -$32.4M | -$76.2M | -$97.2M | -$24.3M | -$91.0M |
| Diluted EPS | — | — | -$1.90 | -$2.32 | -$1.46 | -$1.88 |
| Operating cash flow | -$5.4M | -$30.2M | -$77.5M | -$82.0M | -$116.9M | -$32.3M |
| Free cash flow | — | -$52.4M | -$80.2M | -$82.4M | -$117.0M | -$32.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$61.4M | -$30.6M | -$29.5M | -$24.6M | -$45.4M | -$11.9M | -$13.6M | -$11.2M |
| Net income | $6.2M | -$27.9M | -$27.6M | -$23.4M | -$44.2M | -$10.8M | -$12.5M | -$10.3M |
| Diluted EPS | $0.13 | -$0.58 | -$0.58 | -$0.48 | -$0.92 | -$0.22 | -$0.26 | — |
| Operating cash flow | -$18.2M | -$18.3M | -$61.3M | -$11.3M | -$4.9M | -$6.2M | -$9.7M | -$8.9M |
| Free cash flow | -$18.3M | -$18.3M | -$61.3M | -$11.3M | -$4.9M | -$6.3M | -$10.2M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Mar 12, 2026
Mar 10, 2026
Feb 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-11-24 | Anderson Robert Eugene Jr | Buy | 8,600 | $2.90 | $24,940.00 | filing |
| 2025-11-20 | Barry Richard· President & CEO | Buy | 150,000 | $2.76 | $414,000.00 | filing |
| 2025-11-19 | Barry Richard· President & CEO | Buy | 73,385 | $2.75 | $201,808.75 | filing |
| 2025-09-30 | Cook Robert Christopher· Chief Operating & Legal Office | Buy | 13,725 | $2.91 | $39,939.75 | filing |
| 2025-09-22 | Barry Richard· President & CEO | Buy | 7,172 | $2.28 | $16,352.16 | filing |
| 2025-09-19 | Barry Richard· President & CEO | Buy | 46,908 | $2.29 | $107,419.32 | filing |
| 2025-09-19 | Barry Richard· President & CEO | Buy | 400 | $2.25 | $900.00 | filing |
| 2025-09-18 | Barry Richard· President & CEO | Buy | 185,233 | $2.24 | $414,921.92 | filing |
| 2025-09-18 | Barry Richard· President & CEO | Buy | 5,400 | $2.13 | $11,502.00 | filing |
Latest 9 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.